|
Shripad Bhagwat's more than 20 years of research experience in the pharmaceutical industry are driving Ambit's internal drug discovery efforts. Prior to joining Ambit, he served as Vice President of Drug Discovery at Signal Pharmaceuticals (now Celgene), where he was responsible for managing screening, medicinal chemistry, structure based drug design, PK/ADME and in vivo pharmacology. He also supervised multiple drug discovery projects in cancer and inflammation with a focus on kinases and helped identify six drug candidates, two of which are currently in phase 2 clinical trials. Bhagwat previously served as Senior Group Leader, Neuroscience Research at Abbott Laboratories, where he managed medicinal chemistry, combinatorial chemistry and structure based drug design activities. He also contributed to the drug discovery research at Ciba-Geigy Corporation, where his work led to the identification of three candidates for clinical development. Bhagwat has published over 50 papers and is an inventor on over 40 issued patents or pending patent applications. He received his Ph.D. in organic chemistry from the State University of New York at Stony Brook and conducted postdoctoral research at Columbia University. | 